DK2970232T3 - Substituerede pyridinderivater nyttige som c-fms-kinase-inhibitorer - Google Patents
Substituerede pyridinderivater nyttige som c-fms-kinase-inhibitorer Download PDFInfo
- Publication number
- DK2970232T3 DK2970232T3 DK14729096.9T DK14729096T DK2970232T3 DK 2970232 T3 DK2970232 T3 DK 2970232T3 DK 14729096 T DK14729096 T DK 14729096T DK 2970232 T3 DK2970232 T3 DK 2970232T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- formula
- pyran
- cancer
- deuterated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
Claims (14)
1. Forbindelse med formlen (I)
hvor R1 er valgt fra gruppen bestående af -CH2-OH og -C(0)0H; eller enantiomer, diastereomer, racemat eller farmaceutisk acceptabelt salt deraf.
2. Forbindelse ifølge krav 1, hvor R1 er -C(0)0H.
3. Forbindelse ifølge krav 1, hvor R1 er -CH2-OH.
4. Forbindelse ifølge krav 1, hvor forbindelsen er med formlen (I-M2)
eller enantiomer, diastereomer, racemat eller farmaceutisk acceptabelt salt deraf; hvor forbindelsen med formlen (I-M2) er til stede i en isoleret form eller en i det væsentlige ren form, eller hvor forbindelserne er med formlen (I-M7)
eller enantiomer, diastereomer, racemat eller farmaceutisk acceptabelt salt deraf; hvor forbindelse med formlen (I-M7) er til stede i en isoleret form eller en i det væsentlige ren form.
5. Blanding afen forbindelse med formlen (I-M2-D4a)
og en forbindelse med formlen (I-M2-D4b)
eller en blanding afen forbindelse med formlen (I-M7-D4a)
og en forbindelse med formlen (I-M7-D4b)
6. Farmaceutisk sammensætning omfattende en farmaceutisk acceptabel bærer og en forbindelse ifølge krav 1.
7. Forbindelse ifølge krav 1 eller sammensætningen ifølge krav 6 til anvendelse i en fremgangsmåde til behandling af en lidelse medieret af c-fms-kinase, hvor fremgangsmåden omfatter indgivelse til et individ, som har behov derfor, af en terapeutisk effektiv mængde afen forbindelse ifølge krav 1 eller en sammensætning ifølge krav 6.
8. Forbindelse ifølge krav 1 eller sammensætning ifølge krav 6 til anvendelse ifølge krav 7, hvor lidelsen er valgt fra gruppen bestående af osteoporose, Pagets sygdom, rheumatoid arthritis, andre former for inflammatorisk arthritis, osteoarthritis, prostesesvigt, osteolytisk sarkom, myelom, Hodgkins lymfom, knogletumormetastase, cancer i æggestokkene, livmodercancer, brystcancer, prostatacancer, lungecancer, tyktarmscancer, mavecancer, hairy-cell leukæmi; metastase fra cancer i æggestokkende, livmodercancer, brystcancer, prostatacancer, lungecancer, tyktarmscancer, mavecancer, eller hairy-cell leukæmi; glomerulonefritis, inflammatorisk tarmsygdom, sarkoidose, kongestiv obstruktiv lungesygdom, idiopatisk pulmonal fibrose, astma, pancreatitis, HIV-infektion, psoriasis, diabetes, tumorrelateret angiogenese, aldersrelateret makulær degeneration, diabetisk retinopati, restenose, skizofreni, Alzheimers demens; smerter, knoglesmerter forårsaget af tumormetastase eller osteoarthritis, visceral smerte, inflammatorisk smerte, neurogen smerte; en autoimmun sygdom, systemisk lupus erythematosus, rheumatoid arthritis, andre former for inflammatorisk arthritis, psoriasis, Sjogrens syndrom, multipel sklerose og uveitis, eller hvor lidelsen medieret af c-fms-kinase er rheumatoid arthritis, eller hvor lidelsen medieret af c-fms-kinase er Hodgkins lymfom.
9. Fremgangsmåde til fremstilling afen forbindelse med formlen (I-M2)
eller enantiomer, diastereomer, racemat eller farmaceutisk acceptabelt salt deraf; omfattende
at omsætte n-butyl 4-(5-(4-cyano-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-imidazol-2-carboxamido)-6-(4,4-dimethylcyclohex-l-en-l-yl)pyridin-2-yl)-2,6,6-trimethyltetrahydro-2H-pyran-2-carboxylat med en desilyleringsreagens; i et organisk opløsningsmiddel; ved en temperatur i området fra ca. 0°C til ca. 120°C; for at give n-butyl 4-(5-(4-cyano-lH-imidazol-2-carboxamido)-6-(4,4- dimethylcyclohex-l-en-l-yl)pyridin-2-yl)-2,6,6-trimethyltetrahydro-2H-pyran-2- carboxylat;
at omsætte n-butyl 4-(5-(4-cyano-lH-imidazol-2-carboxamido)-6-(4,4-d imethylcyclohex- 1-en-l-yl)pyridin-2-y 1)-2,6,6-trimethyltetrahydro-2H-pyran-2-carboxylat og syre eller base; for at give den tilsvarende forbindelse med formlen (I-M2).
10. Fremgangsmåde til fremstilling afen forbindelse med formlen (I-M7)
eller enantiomer, distereomer, racemat eller farmaceutisk acceptabelt salt deraf; omfattende
at omsætte n-butyl 4-(5-(4-cyano-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-imidazol-2-carboxamido)-6-(4,4-dimethylcyclohex-l-en-l-yl)pyridin-2-yl)-2,6,6-trimethyltetrahydro-2H-pyran-2-carboxylat med et reduktionsmiddel; i et organisk opløsningsmiddel; ved en temperatur i området fra ca. -80°C til ca. 50°C; for at give 4-cyano-N-(2-(4,4-dimethylcyclohex- 1-en-l-yl)-6-(2-(hydroxymethyl)-2,6,6- trimethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-lH-imidazol-2-carboxamid;
at omsætte 4-cyano-N-(2-(4,4-dimethylcyclohex-l-en-l-yl)-6-(2-(hydroxymethyl)-2,6,6-trimethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-imidazol-2-carboxamid med en desilyleringsreagens; i et organisk opløsningsmiddel; ved en temperatur i området fra ca. 0°C til ca. 110°C; for at give den tilsvarende forbindelse med formlen (I-M7).
11. Forbindelse ifølge krav 1 til anvendelse som et medikament.
12. Forbindelse ifølge krav 1, valgt fra gruppen bestående afen forbindelse med formlen (I-M2-2R,4S)
og en forbindelse med formlen (I-M2-2S,4R)
13. Forbindelse ifølge krav 1, valgt fra gruppen bestående af en forbindelse med formlen I-M7-2R,4S)
og en forbindelse med formlen (I-M7-2S,4R)
14. Forbindelse ifølge et hvilket som helst af kravene 1, 2, 3, 12 eller 13, hvor forbindelsen er til stede i en isoleret form eller en i det væsentlige ren form.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791007P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/025308 WO2014151258A1 (en) | 2013-03-15 | 2014-03-13 | Substituted pyridine derivatives useful as c-fms kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970232T3 true DK2970232T3 (da) | 2018-04-09 |
Family
ID=50897867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14729096.9T DK2970232T3 (da) | 2013-03-15 | 2014-03-13 | Substituerede pyridinderivater nyttige som c-fms-kinase-inhibitorer |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9611259B2 (da) |
| EP (2) | EP3284742A1 (da) |
| JP (1) | JP6384022B2 (da) |
| CN (2) | CN108341805A (da) |
| AU (1) | AU2014235183B9 (da) |
| CY (1) | CY1120185T1 (da) |
| DK (1) | DK2970232T3 (da) |
| ES (1) | ES2662600T3 (da) |
| HK (3) | HK1212339A1 (da) |
| HR (1) | HRP20180632T1 (da) |
| HU (1) | HUE036925T2 (da) |
| LT (1) | LT2970232T (da) |
| MX (1) | MX365315B (da) |
| NO (1) | NO3090256T3 (da) |
| PL (1) | PL2970232T3 (da) |
| PT (1) | PT2970232T (da) |
| RS (1) | RS57103B1 (da) |
| SI (1) | SI2970232T1 (da) |
| WO (1) | WO2014151258A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2970232T3 (pl) | 2013-03-15 | 2018-08-31 | Janssen Pharmaceutica Nv | Podstawione pochodne pirydyny użyteczne jako inhibitory kinazy c-FMS |
| TW201811326A (zh) * | 2016-07-18 | 2018-04-01 | 比利時商健生藥品公司 | ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式 |
| TWI752980B (zh) * | 2016-07-18 | 2022-01-21 | 比利時商健生藥品公司 | 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型 |
| WO2018160917A1 (en) * | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| WO2018182527A1 (en) * | 2017-03-30 | 2018-10-04 | National University Of Singapore | Method for treating inflammatory complications in eye diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| KR101273434B1 (ko) | 2004-10-22 | 2013-06-11 | 얀센 파마슈티카 엔.브이. | Ｃ-ｆｍｓ 키나제의 저해제 |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| PL2970232T3 (pl) * | 2013-03-15 | 2018-08-31 | Janssen Pharmaceutica Nv | Podstawione pochodne pirydyny użyteczne jako inhibitory kinazy c-FMS |
-
2014
- 2014-03-13 PL PL14729096T patent/PL2970232T3/pl unknown
- 2014-03-13 RS RS20180441A patent/RS57103B1/sr unknown
- 2014-03-13 AU AU2014235183A patent/AU2014235183B9/en active Active
- 2014-03-13 WO PCT/US2014/025308 patent/WO2014151258A1/en active Application Filing
- 2014-03-13 PT PT147290969T patent/PT2970232T/pt unknown
- 2014-03-13 CN CN201810396318.4A patent/CN108341805A/zh active Pending
- 2014-03-13 JP JP2016501816A patent/JP6384022B2/ja active Active
- 2014-03-13 MX MX2015012343A patent/MX365315B/es active IP Right Grant
- 2014-03-13 HU HUE14729096A patent/HUE036925T2/hu unknown
- 2014-03-13 US US14/772,040 patent/US9611259B2/en active Active
- 2014-03-13 SI SI201430613T patent/SI2970232T1/en unknown
- 2014-03-13 EP EP17190920.3A patent/EP3284742A1/en not_active Withdrawn
- 2014-03-13 EP EP14729096.9A patent/EP2970232B1/en active Active
- 2014-03-13 LT LTEP14729096.9T patent/LT2970232T/lt unknown
- 2014-03-13 ES ES14729096.9T patent/ES2662600T3/es active Active
- 2014-03-13 DK DK14729096.9T patent/DK2970232T3/da active
- 2014-03-13 CN CN201480015688.9A patent/CN105026388B/zh active Active
- 2014-12-02 NO NO14824967A patent/NO3090256T3/no unknown
-
2016
- 2016-01-11 HK HK16100226.8A patent/HK1212339A1/xx unknown
-
2017
- 2017-02-23 US US15/440,182 patent/US10071991B2/en active Active
-
2018
- 2018-04-20 HR HRP20180632TT patent/HRP20180632T1/hr unknown
- 2018-04-27 CY CY20181100448T patent/CY1120185T1/el unknown
- 2018-08-13 US US16/102,005 patent/US10800764B2/en active Active
- 2018-08-15 HK HK18110479.9A patent/HK1250986A1/zh unknown
-
2019
- 2019-01-28 HK HK19101388.7A patent/HK1258911A1/zh unknown
-
2020
- 2020-09-02 US US17/010,132 patent/US11214566B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11214566B2 (en) | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | |
| KR102396717B1 (ko) | Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료 | |
| EP1960372B1 (en) | Kinase inhibitors and their uses | |
| AU2018304757A1 (en) | Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor | |
| CA2880447A1 (en) | 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | |
| CN113365997B (zh) | 作为c-Met抑制剂的含嘧啶基团的三并环类化合物 | |
| AU2009287621A1 (en) | Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors | |
| KR20190026731A (ko) | 베타-3 아드레날린성 수용체와 관련된 장애의 치료 또는 예방에 유용한 베타-3 아드레날린성 수용체의 조정제 | |
| KR20210003175A (ko) | p300 및/또는 CBP의 조절제를 제조하는 방법 | |
| EA030034B1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| CA3009324A1 (en) | Cortistatin analogs and uses thereof | |
| EA025100B1 (ru) | Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth | |
| EP3283487B1 (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
| EP2882744A1 (en) | Process for the preparation of c-fms kinase inhibitors | |
| JP6617106B2 (ja) | 癌の治療用のｆａｓｎ阻害剤として有用なイミダゾリン−５−オン誘導体 | |
| CN101223158B (zh) | N-二羟基烷基取代2-氧代咪唑衍生物 | |
| AU2022255486A1 (en) | Nek7 inhibitors | |
| RU2820477C1 (ru) | Производные 5-окса-2-азаспиро[3.4]октана в качестве агонистов m4 | |
| US20240190842A1 (en) | Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof | |
| KR20230145079A (ko) | 암의 치료를 위한 mcl-1 억제제로서의 마크로사이클릭1,3-브릿지된 6-클로로-7-피라졸-4-일-1h-인돌-2-카르복실레이트 및 6-클로로-7-피리미딘-5-일-1h-인돌-2-카르복실레이트 유도체 | |
| TW202204357A (zh) | 黑皮質素4(melanocortin 4)受體拮抗劑及其用途 | |
| WO2023049270A1 (en) | Pyrrole[2,3-b]pyridine derivatives as tyro3 inhibitors |